Compare GSK plc (GSK) vs Oatly Group AB - ADR (OTLY) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

OTLY trades at $9.97, up 2.15% today, with a bullish technical signal despite mixed moving averages. Revenue grew to $862M in 2025, but net losses persist at -$153M. The company maintains a strong brand presence, with recent product expansions in Canada and a partnership with Nespresso. Cash burn remains a concern, with negative operating cash flow of -$24M in 2025. Analyst consensus is divided, with 44% buy ratings but 50% hold, reflecting cautious optimism amid financial challenges.

Outlook: OTLY shows potential for growth through market expansion and cost management, but high debt and sustained losses pose significant risks. Investment appeal hinges on achieving profitability and reducing cash burn. Key catalysts include Q2 2026 earnings on July 22, 2026, and execution of strategic initiatives. Risks include liquidity constraints and competitive pressures in the plant-based beverage sector.